Table 1.
VNT50 values of MCMVS-immunized mouse serum samples against SARS-CoV-2 or pseudotyped VSV-S
| Neutralization (pVNT50 and VNT50) | |||||
|---|---|---|---|---|---|
| Pseudotyped VSV-S | SARS-CoV-2 (FI strain) | ||||
| WH01 | MCMVS | MCMVS | |||
| +D614G | B1.1.7 | B1.351 | (Total Ig isotypes) | (IgG isotypes) | |
| day 7 | 1:84.09 | 1:10.70 | |||
| (33.69–231.6) | (2.54–20.83) | ||||
| day 14 | 1:55.93 | 1:31.90 | |||
| (23.36–133.4) | (13.37–63.53) | ||||
| day 28 | 1:227.5 | 1:202.5 | |||
| (168–429.5) | (104.7–332.2) | ||||
| day 56 | 1:910.5 | 1:945.2 | 1:450.6 | 1:476.4 | 1:407 |
| (399.2–1251) | (275.7–883.3) | ||||
The table indicates the average VNT50 or pVNT50 values against SARS-CoV-2 or pseudotyped VSV-S of serum samples collected from immunized mice at the indicated time points. The neutralizing antibody titers were calculated by nonlinear IC50 regression analysis in GraphPad Prism 9. The indicated VNT50 or pVNT50 values denote the serum dilutions that resulted in a 50% reduction of virus plaques or of VSV luciferase activity.